Stargardt disease (STGD1) is the most frequent hereditary macular dystrophy. It is characterized by a progressive loss of central vision and is associated, in most cases, with biallelic variants in the ABCA4 gene. These alterations favor the accumulation of toxic retinoid compounds in the retina, damaging the retinal pigment epithelium and photoreceptors.
Stargardt disease
The ABCA4 gene encodes a transporter protein located in the outer segments of photoreceptors in the retina, both cones and rods. Its function is to remove derivatives from the visual cycle, such as N-retinylidene phosphatidylethanolamine, so that they can be properly processed and eliminated.
When pathogenic variants exist in ABCA4, this transport function is reduced or lost. As a consequence, bisretinoids and lipofuscin accumulate in the retinal pigment epithelium, especially in the macular region, leading to progressive damage of photoreceptors and loss of central vision. ABCA4-associated disease usually follows an autosomal recessive pattern, meaning an affected person typically inherits one pathogenic variant from each parent. Stargardt-like phenotypes can be caused by other genes and present with other inheritance patterns. Stargardt disease is the most common inherited macular dystrophy, with an approximate prevalence of 1 in 8,000 to 10,000 people.
Symptoms
Onset usually occurs in late childhood, adolescence, or young adulthood, although there are later onset forms. The main symptom is progressive loss of central visual acuity, which may be accompanied by a central scotoma, difficulty reading or recognizing faces, altered color perception, and slow adaptation to darkness. Peripheral vision is usually preserved for a long time, although it may be affected in stages.
Disease management
Currently, there is no cure or approved pharmacological treatment that definitively stops the progression of Stargardt disease. Management focuses on specialized ophthalmological monitoring, low vision aids, and measures to reduce retinal stress, such as avoiding intense sun exposure and using UV-protective glasses. High-dose vitamin A or beta-carotene supplements are recommended to be avoided, unless medically indicated. There are ongoing trials with visual cycle modulators, gene therapies, oligonucleotides, and cell therapies.
Genes analyzed
Bibliography
Cornelis SS, Runhart EH, Bauwens M, et al. Personalized genetic counseling for Stargardt disease: Offspring risk estimates based on variant severity. Am J Hum Genet. 2022 Mar 3;109(3):498-507.
Dayma K, Rajanala K, Upadhyay A. Stargardt's Disease: Molecular Pathogenesis and Current Therapeutic Landscape. Int J Mol Sci. 2025 Jul 21;26(14):7006.
Wang L, Shah SM, Mangwani-Mordani S, et al. Updates on Emerging Interventions for Autosomal Recessive ABCA4-Associated Stargardt Disease. J Clin Med. 2023 Sep 27;12(19):6229.
Molday RS, Garces FA, Scortecci JF, et al. Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration. Prog Retin Eye Res. 2022 Jul;89:101036.
